Kaempferol 3-neohesperidoside
(Synonyms: 堪非醇3-新橙皮糖苷,Kaempferol 3-O-neohesperidoside) 目录号 : GC60213
A flavonoid with antioxidant and antidiabetic activities
Cas No.:32602-81-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kaempferol 3-neohesperidoside is a flavonoid that has been found in D. calycinum and has antioxidant and antidiabetic activities.1,2,3,4 It scavenges DPPH radicals in a cell-free assay (IC50 = 79.6 ?g/ml).1 Kaempferol 3-neohesperidoside (1 and 100 nM) increases glucose uptake in isolated rat soleus muscle.2 It also increases glycogen synthesis in isolated rat soleus muscle, an effect that can be blocked by the PI3K inhibitor wortmannin and the MEK inhibitor PD 98059 , when used at a concentration of 1 ?M.3 Kaempferol 3-neohesperidoside (100 mg/kg) reduces serum glucose levels in a rat model of diabetes induced by alloxan .4
1.Gamez, E.J.C., Luyengi, L., Lee, S.K., et al.Antioxidant flavonoid glycosides from Daphniphyllum calycinumJ. Nat. Prod.61(5)706-708(1998) 2.Zanatta, L., Rosso, ?., Folador, P., et al.Insulinomimetic effect of kaempferol 3-neohesperidoside on the rat soleus muscleJ. Nat. Prod.71(4)532-535(2008) 3.Cazarolli, L.H., Folador, P., Pizzolatti, M.G., et al.Signaling pathways of kaempferol-3-neohesperidoside in glycogen synthesis in rat soleus muscleBiochimie91(7)843-849(2009) 4.Cazarolli, L.H., Zanatta, L., Jorge, A.P., et al.Follow-up studies on glycosylated flavonoids and their complexes with vanadium: Their anti-hyperglycemic potential role in diabetesChem. Biol. Interact.163(3)177-191(2006)
| Cas No. | 32602-81-6 | SDF | |
| 别名 | 堪非醇3-新橙皮糖苷,Kaempferol 3-O-neohesperidoside | ||
| Canonical SMILES | O=C1C(O[C@H](O[C@@H]2CO)[C@@H]([C@H]([C@@H]2O)O)O[C@H](O[C@H]3C)[C@@H]([C@@H]([C@H]3O)O)O)=C(C(C=C4)=CC=C4O)OC5=CC(O)=CC(O)=C15 | ||
| 分子式 | C27H30O15 | 分子量 | 594.52 |
| 溶解度 | 储存条件 | ||
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.682 mL | 8.4101 mL | 16.8203 mL |
| 5 mM | 0.3364 mL | 1.682 mL | 3.3641 mL |
| 10 mM | 0.1682 mL | 0.841 mL | 1.682 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Signaling pathways of kaempferol-3-neohesperidoside in glycogen synthesis in rat soleus muscle
Biochimie 2009 Jul;91(7):843-9.PMID:19376191DOI:10.1016/j.biochi.2009.04.004.
Kaempferol 3-neohesperidoside is one of the several compounds that have been reported to have insulin-like properties in terms of glucose lowering. We studied the effect of Kaempferol 3-neohesperidoside in glycogen synthesis in rat soleus muscle through the incorporation of (14)C-d-glucose in glycogen. Kaempferol 3-neohesperidoside stimulates glycogen synthesis in rat soleus muscle by approximately 2.38-fold. Insulin at 100 nM showed a stimulatory effect on glycogen synthesis when compared with the control group. The stimulatory effect of kaempferol 3-neophesperidoside on glycogen synthesis was inhibited by wortmannin, the phosphatidylinositol 3-kinase (PI3K) inhibitor, and enhanced by lithium chloride, a glycogen synthase kinase 3 (GSK-3) inhibitor. Moreover, the stimulatory effect of Kaempferol 3-neohesperidoside was also nullified by PD98059, a specific inhibitor of mitogen-activated protein kinase (MEK) and by calyculin A, an inhibitor of protein phosphatase 1 (PP1) activity. It was concluded that the PI3K - GSK-3 pathway and MAPK - PP1 pathway are involved in the stimulatory Kaempferol 3-neohesperidoside effect on glycogen synthesis in rat soleus muscle.
Insulinomimetic effect of Kaempferol 3-neohesperidoside on the rat soleus muscle
J Nat Prod 2008 Apr;71(4):532-5.PMID:18303854DOI:10.1021/np070358+.
A stimulatory effect of Kaempferol 3-neohesperidoside ( 1) on glucose uptake (35% and 21%) was observed when the rat soleus muscle was incubated with 1 and 100 nM of this flavonoid glycoside, respectively. The concentration-response curve of insulin showed a stimulatory effect at 3.5 and 7.0 nM (42% and 50%) on glucose uptake when compared with the control group. The effect of 1 on glucose uptake was completely nullified by pretreatment with LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), and RO318220, an inhibitor of protein kinase C (PKC). However, no significant change occurred on glucose uptake stimulated by 1 when muscles were pretreated with PD98059, an inhibitor of mitogen-activated protein kinase (MEK), and cycloheximide, an inhibitor of protein synthesis. Compound 1 and insulin (7 nM) did not show a synergistic effect on glucose uptake. Additionally, 100 mg/kg of 1 by oral gavage was able to increase glycogen content in the muscle. These results suggest that 1 stimulates glucose uptake in the rat soleus muscle via the PI3K and PKC pathways and, at least in part, independently of MEK pathways and the synthesis of new glucose transporters.
A new natural naphtho[1,2-b]furan from the leaves of Cassia fistula
J Asian Nat Prod Res 2013 Nov;15(11):1210-3.PMID:23822190DOI:10.1080/10286020.2013.812077.
A new naphtho[1,2-b]furan, 2,9-dihydroxy-7-methoxy-4-methylnaphtha[1,2-b]furan-3(2H)-one (1), along with 10 known compounds vanillic acid (2), naringenin (3), glyceryl-1-tetracosanoate (4), moracin J (5), 1,3,8-trihydroxyanthraquinone (6), esculetin (7), mauritianin (8), Kaempferol 3-neohesperidoside (9), β-sitosterol (10), and β-daucosterol (11), was isolated from the leaves of Cassia fistula. The structure of the new compound was determined by NMR and X-ray analysis. Compounds 1, 3, 5-9 were isolated from this plant for the first time. The naphtha[1,2-b]furan was firstly isolated from the natural resources.
Primula latifolia Lapeyr. and Primula vulgaris Hudson flavonoids
Nat Prod Res 2014;28(19):1641-4.PMID:24969099DOI:10.1080/14786419.2014.924003.
Three flavonoids were isolated from the leaf MeOH extracts of Primula latifolia Lapeyr. and Primula vulgaris Hudson collected from Italian Alps: rutin (1) and Kaempferol 3-neohesperidoside (2) from P. latifolia, and kaempferol 3-β-O-glucopyranosyl-(1 → 2) gentiobioside (3) from P. vulgaris. The structures were assigned on the basis of their (1)H and (13)C NMR data, including those derived from 2D NMR, as well as on HPLC-MS results. This article is the first to report on P. vulgaris tissue flavonoids after Harborne's study in 1968 and the first work ever on these compounds from P. latifolia.
Screening of honey bee pollen constituents against COVID-19: an emerging hot spot in targeting SARS-CoV-2-ACE-2 interaction
Nat Prod Res 2023 Mar;37(6):974-980.PMID:35758279DOI:10.1080/14786419.2022.2092865.
The attachment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike to angiotensin-converting enzyme 2 (ACE-2) leads the cell fusion process, so spike blockade may be a promising therapy combating COVID-19. Bee pollen bioflavonoids with intrinsic bioactivities are of outmost importance to block SARS-CoV-2-ACE-2 interaction. Herein, we conducted a molecular docking assessment through natural phenolics/non-phenolics of pollen to investigate their affinity against SARS-CoV-2 spike. Finally, Kaempferol 3-neohesperidoside 7-O-rhamnoside (compound a), quercetin 7-rhamnoside (compound b), delphinidin-3-O-(6-p-coumaroyl) glucoside (compound c), and luteolin-7-O-6″-malonylglucoside (compound d) showed the lowest binding affinity of -8.1, -7.7, -7.3 and -6.7 kcal/mol. The docking procedure was validated using protein-protein interactions between ACE-2 and SARS-CoV-2 RBD via HADDOCK webserver. MD simulations were fulfilled to investigate different ligands' effects on protein movements. Collectively, compound a may possess the potency to disturb the binding of SARS-CoV-2 spike-ACE-2, which can be on the call for further in vitro and in vivo study to investigate its antiviral potential against SARS-CoV-2.